Mektovi
What Mektovi is used for
MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Mektovi
- Active substance
- binimetinib
- Disease area
- Melanoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01EE03
- Marketing authorisation holder
- Pierre Fabre Medicament
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mektovi used for?
MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
What is the active substance in Mektovi?
Mektovi contains binimetinib.
Who makes Mektovi?
The EU marketing authorisation holder is Pierre Fabre Medicament.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU